Skip to content
Clinical Trials – home
Verifiedinfo

Instituto Oftalmologico Gomez-Ulla S.L.

Spain Rua De Maruxa Mallo No 3, 15706 Santiago De Compostela, Spain

  • 3 trials recruiting
  • Dry age-related macular degeneration · Diabetic retinal oedema · Age-related macular degeneration
  • Adult patients

About Specializations

Instituto Oftalmologico Gomez-Ulla S.L. in Santiago De Compostela, Spain specialises in clinical trials of conditions such as Dry age-related macular degeneration, Diabetic retinal oedema, Age-related macular degeneration, Atopic keratoconjunctivitis, and other specialisations. This site conducts important research.

Main research areas of the site

Eye Diseases and Retinal Degeneration Research

At Instituto Oftalmologico Gomez-Ulla S.L., clinical research in ophthalmology focuses on eye diseases linked to progressive vision loss, especially geographic atrophy associated with age-related macular degeneration. These studies are designed to better understand long-term treatment safety and to explore whether new therapies can help slow disease progression and protect remaining vision.

  • Long-term safety of treatments for geographic atrophy
  • Evaluation of new options for age-related macular degeneration
  • Assessment of treatment effects on retinal lesion growth

Overall, this work reflects a strong interest in improving care for chronic retinal conditions through therapies aimed at preserving vision and supporting patients over time.

Allergic Eye Disease and Symptom Relief Studies

Another key area at this hospital/clinic is research on atopic keratoconjunctivitis, a painful and persistent allergic condition affecting the eyes. The trials in this area are focused on testing whether new eye treatments can reduce ocular itching and improve day-to-day comfort for adults living with this condition.

  • Testing new therapy for atopic keratoconjunctivitis
  • Improving relief of ocular itching
  • Evaluating symptom control in allergic eye disease

This research highlights a practical goal: finding safer and more effective ways to ease symptoms that can significantly affect quality of life.

Clinical Research on Long-Term Treatment Performance

The site also contributes to studies that follow patients over time to understand how well emerging ophthalmic therapies continue to perform after initial treatment. In particular, the research includes work on treatments for geographic atrophy secondary to age-related macular degeneration, with attention to safety, durability, and possible benefit in slowing retinal damage.

  • Long-term safety evaluation of ophthalmic treatments
  • Monitoring disease progression in geographic atrophy
  • Studying sustained benefit in retinal disease

These trials support a broader effort to improve treatment strategies for patients with chronic, sight-threatening conditions.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Rua De Maruxa Mallo No 315706 Santiago De CompostelaSpain
Recruiting now
3 trials
Conditions studied
7
Partner status
Verified

More sites in Santiago De CompostelaSpain

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

9 clinical trials

Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept
  • Sponsor:Eyebiotech Limited
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Sponsor:Novartis Pharma AG
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:(3S,6S,9S,12R,15S,18S,21S,24S,30S,33S,34R)-30-Ethyl-34-[(E,2R)-Hex-4-En-2-Yl]-4,7,10,12,15,19,25,28-Octamethyl-33-(Methylamino)-6,9,18,24-Tetrakis(2-Methylpropyl)-3,21-Di(Propan-2-Yl)-1-Oxa-4,7,10,13,16,19,22,25,28,31-Decazacyclotetratriacontane-2,5,8,11,14,17,20,23,26,29,32-Undecone Hydrochloride
  • Sponsor:Dompe' Farmaceutici S.p.A.
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept
  • Sponsor:4d Molecular Therapeutics Inc.
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Eye103
  • Sponsor:Eyebiotech Limited
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Pegcetacoplan
  • Sponsor:Apellis Pharmaceuticals Inc.
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept
  • Sponsor:Bayer AG
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Avacincaptad Pegol
  • Sponsor:Astellas Pharma Global Development Inc.
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Eye103
  • Sponsor:Eyebiotech Limited
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.